The latest three-day news flow is not noise: Lexicon has paired a stronger cash runway with fresh pipeline timing around ZYNQUISTA, SONATA-HCM and Novo Nordisk’s LX9851. The setup is improved, but still catalyst-driven and high-risk.
ABCL635 produced an 83% week-4 reduction in moderate-to-severe hot-flash frequency versus 33% on placebo, with no serious adverse events or liver signal. One day later AbCellera launched a proposed US$200 million primary offering of common shares and pre-funded warrants to fund ABCL635 and general corporate purposes. The offering priced on August 12 at US$9.75 per share: 17,435,897 common shares plus pre-funded warrants for a further 3,076,926 shares, US$200.0 million gross, with delivery on or about August 14.
IREN owns power-connected data centre capacity and is converting it from Bitcoin mining to contracted AI cloud services. The handover is visible quarter by quarter: AI Cloud revenue has roughly doubled each quarter while mining revenue has more than halved, and total revenue is falling while it happens.
YARTEMLEA generated $28.5 million of Q2 net revenue, up from $9.9 million in Q1, and Omeros reached reported operating breakeven. The June cash figure precedes July convertible-note repurchases with an aggregate $60.2 million purchase price plus approximately $0.2 million of accrued interest, so commercial momentum and post-transaction liquidity must be read together.
https://www.merlintrader.com/ondas-holdings-hub-2026-coverage/
Verified through August 13, 2026: Ondas reported record second-quarter revenue of $83.8 million, up 67% sequentially and more than thirteenfold year on year, and raised its full-year target to $525 million to $550 million. The same quarter carried $199.1 million of operating expenses, an adjusted EBITDA loss of $50.6 million and a net loss of $89.7 million. Pro forma backlog reached $757 million and cash, restricted cash and short-term investments stood at $1.39 billion.
Merlintrader’s ranking of ten listed biotech companies with the strongest current combination of near-term catalysts, scientific credibility, financial resilience and clearly identifiable risk.